REFERENCES
- Lecciones J, Lee J, Navarro E. Vascular catheter-associ-ated fungemia in patients with cancer. Chin Infect Dis 1992; 16: 875–887.
- Tilley G, Roberts F. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical set-tings. Clin Infect Dis 1994; 18: 896–899.
- EORTC Antimicrobial Therapy Group. Prospective comparison of three antibiotic regimens for empirical therapy of suspected infection in febrile granulocytopenia patients. J Infect Dis 1978; 137, 1: 22–29.
- EORTC International Antimicrobial Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients. N Engl J Med 1987; 317: 1692–1698.
- EORTC International Antimicrobial Group. Vancomycin added to empirical combination antibiotic thera-py for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951–958.
- Meunier F, and the EORTC Antimicrobial Therapy Group. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic thera-py of febrile granulocytopenic cancer patients with lym-phomas and solid tumors. Antimicrob Agents Chemother 1991; 38: 873–878.
- EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–593. EORTC International Antimicrobial Therapy Cooperative Group. A prospective double blind study of pefloxadn plus penicillin or placebo for prophylaxis of bacte-rial infections in granulocytopenic cancer patients. 32-ICAAC, 1992; Anaheim, Abstract No. 1692.
- Gaya H and the International Antimicrobial Therapy Cooperative Group. Piperacillin/ tazobactam plus amikacin versus ceftazidime plus amikacin as empirical therapy for fever in patients with granulocytopenia. ICAAC, 1993; New Orleans, Abstract No. 645.
- EORTC International Antimicrobial Therapy Cooperative Group. A randomized study on meropenem ver-sus ceftazidime plus amikacin in febrile granulocytopenic patients. 34-ICAAC, 1994 Orlando, Abstract No. 1193.
- Kern W, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant E. colt at a cancer center. Antimicrob Agents Chemother 1994; 38, 4: 38-40.
- Cometta A, Calandra T, Bille T, Galazzo J, Giddey M, Glauser M. Quinolone resistant E. colt bacteremias in neu-tropenic cancer patients. In: Proceedings of the IHS sympo-sium, 22.-26.6. 1994, Davos, Abstract n. 84.
- Carratala J, Swilla F, Tubau F, Callis M, Gudiol F. Emergence of quinolone resistant E. colt bacteremia in neu-tropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557–560.
- Noskin G, Peterson RL, Warren J. Enterococcus faeci-urn and Enterococcus faecalis bacteremia. Clin Infect Dis 1995; 20: 296–301.
- Bochud P, Eggimann P, Calandro T, Melle G, Saghabi L, Franciol P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18, 1: 25–29.
- Krcmery V Jr, Trupl J. Outbreak of nosocomial meropenem resistant Ps. aeruginosa infections in a cancer cen-ter. J Hosp Infect 1994; 26: 69–78.
- Wingard JR, Merz WG, Rinaldi M. Increase in C. kru-sei infections among patients with bone marrow transplanta-tion and neutropenia treated prophylactically with flucona-zole. N Engl J Med 1991; 325: 1274–7.
- Viscoli C. Surveillance of fungemias in cancer centers. EORTC study. 6th BICON annual meeting, Bratislava, 19.-23.3. 1995, Abstract No. 33.
- Chow J, Fine M, Shlaes DM, et al. Enterobacter bac-teremia: clinical features and emergence of resistance. Ann Infect Med 1991; 115, 8: 585–589.
- Rosenthal EJ. Epidemiology of the microorganisms causing septicaemia: a multicenter blood culture study. Dtsch Med Wschr 1993; 12: 1269–1279.